• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens.
    All the platforms and services are label-free with no modification of the original molecules.

    Target & MoA Deconvolution
    Target Validation & Engagement

    Lead Compound Selection

    Patient Cohort Stratification

    Indication Prioritization

    Biomarker Discovery

    SPR and Proteomics

    Human Biological Samples Provision

  • Platforms

    Platforms

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    NPOT®

    Unlocking drug mechanism of action in native biological contexts

    Read more

    PIMS®

    Designed to study molecular interactions and predict therapeutic responses in biomedical research

    Read more

    LIPS

    Designed to measure drug-target interactions with high accuracy in native environments, including cultured cells and patient tissues.

    Read more

    Biomarkers discovery

    Methodology for the proteomic profiling of human individuals in the context of translational evaluation of biomarkers and clinical development of new drug candidates.

    Read more

  • Expertise

    Our expertise in translational pharmacology

    Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

    Translational pharmacology expertise

    Pre-clinical to clinical phases

    Read more

    Our innovative approach

    Biomarkers, patient and therapeutic window

    Read more

    Advantages of approach

    Save time and money

    Read more

    How we work with clients

    Tailored methodologies and technologies 

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us

PIMS®

Physiological Intermolecular Modulation Spectroscopy

PIMS® is a patented, label-free biophysical and analytical technology designed to study molecular interactions and predict therapeutic responses in biomedical research.

By leveraging near-infrared (NIR) spectroscopy, PIMS® detects subtle nanoscale modification when proteins and other biomolecules interact with drugs or other exogenous molecules. This unique approach generates dynamic “fingerprints” of a biological sample’s macromolecular structure and signalling activity, offering powerful insights into tissue response and personalized treatment outcomes.

The concept

Label-free analysis:
PIMS® operates without the need for fluorescent or radioactive labels, preserving the native state of the biological sample. It examines protein–protein and protein–solvent interactions within complex, multicomponent solutions such as blood, tissues, and PBMCs.

Water molecule resonance as a probe:
When a drug engages its target, the resulting macromolecular conformational shift alters the water resonance). This modulation provides a measurable, specific fingerprint of the treatment’s effect on molecular architecture and associated signalling pathways.

Complementary integration with NPOT®:
In tandem with the Nematic Protein Organization Technic (NPOT®), PIMS® can map the spatial organization and functional networks of proteins. This combined approach is invaluable for deciphering the mechanisms behind drug response and identifying predictive biomarkers

How PIMS® works:

  • Dynamic fingerprinting:
    PIMS® records a baseline spectral profile of a patient’s biological sample, then measures the changes after introducing a drug or compound. The resulting spectrum reflects changes in macromolecular conformation and water molecule resonance, indicating the activation (or lack thereof) of specific pharmacological signalling pathways.
  • Mechanism in brief:
    • Sample analysis: Biological samples (e.g., blood, Plasma, Tissues, PBMCs) are challenged with a therapeutic agent.
    • NIR spectroscopy: When a compound interacts with its target protein, it can induce conformational changes in the protein’s structure. These changes can alter the surrounding water molecules network, leading to a shift from high-density to low-density water structures or vice versa. PIMS measures these shifts in water molecule resonance to provide insights into the macromolecular interactions occurring within the sample.
    • Signal readout: This modulation is captured as a real-time, dynamic fingerprint that differentiates responders from non-responders.

Key applications:

Personalized medicine & patient stratification:

PIMS® is used ex vivo to classify patients as good, partial, or non-responders by challenging their samples with drugs or drug combinations (e.g. lead compound plus a marketed monoclonal antibody). This stratification ensures that the most effective therapeutic strategies are selected on a patient-by-patient basis.

Disease profiling

PIMS® can distinguish between metastatic and non-metastatic patients by comparing the spectra generated with PIMS® with tumour biopsies

Biomarker development & mechanistic studies

The technology not only predicts treatment efficacy but also guides the identification of molecular networks and biomarkers. This dual readout (macromolecular conformation and water resonance) paves the way for mechanistic insights into drug action and resistance.

Methodology and workflow

  • Sample preparation:
    Biological samples are collected from patients prior to therapy. These samples—whether blood, PBMCs, or tissues—are then incubated with the drug candidate or combination of compounds.
  • Label-free, real-time detection:
    Using NIR spectroscopy, PIMS® detects the minute shifts in water molecule resonance as the drug engages its target, triggering downstream signaling cascades. In the absence of such engagement, no significant spectral change is observed.
  • Data integration with NPOT®:
    After stratifying patients based on their PIMS® fingerprint, NPOT® is often applied to resolve the specific signalling pathways and protein networks responsible for the observed response patterns. This two-step process provides both a predictive and mechanistic understanding of treatment efficacy.
Inoviem - PIMS workflow - stratification patient

Advantages:

Non-Invasive, holistic & rapid

The NIR approach allows for quick, non-destructive analysis without extensive sample preparation.

High specificity

PIMS® delivers precise molecular fingerprints, enabling accurate patient stratification and predictive diagnostics.

Personalized insights

By reflecting individual variations in macromolecular architecture, the technology supports personalized treatment strategies and biomarker discovery.

Why choose PIMS® at Inoviem Scientific?

At Inoviem, our commitment to cutting-edge, label-free biophysical technologies like PIMS® is at the heart of advancing personalized medicine. By providing rapid, reliable insights into how patients respond to therapeutic interventions, PIMS® is transforming drug development and clinical diagnostics—ensuring that the right treatment is delivered to the right patient.

See a PIMS® case study in Inflammatory Bowel Disease (IBD)

PIMS® has been applied to predict responses to vedolizumab therapy in patients with anti-TNF refractory IBD (including Crohn’s disease and ulcerative colitis). Clinical studies have demonstrated an 89% positive predictive value and an 82% negative predictive value, while also highlighting specific biomarkers (e.g., ITGB7, ITGAV, PF4) associated with a positive therapeutic response.

See this case study

Headquarter
Bioparc 2, 850 boulevard Sébastien Brant,
67400 Illkirch-Graffenstaden

CONTACT US


SERVICES
EXPERTISE

Our expertise in translational pharmacology
Advantages of a translational pharmacology approach
How we work with clients

PLATFORMS

NPOT®
PIMS®
LIPS
Biomarkers discovery

KNOWLEDGE CENTER
ABOUT US

Our mission
Our team

PRIVACY POLICY
Need Help